Similar immune signature was previously reported in EGFR mutation-positive non-small-cell lung cancer (NSCLC) [28–30], in which, elevated PD-L1 in EGFR mutant tumor was consider to be an indicator of better overall response rate to PD-1 inhibitors. This evidence concerns the gene EGFR and neoplasm.